The Senate Appropriations Committee on July 27 passed the Labor, Health and Human Services, Education, and Related Agencies FY 2024 spending bill, which includes $47.8 billion in funding for the National Institutes of Health (NIH), $7.38 billion for the National Cancer Institute (NCI) and $1.5 billion for the Advanced Research Projects Agency on Health (ARPA-H).

A statement from Everett E. Vokes, MD, FASCO, Chair of the Board, Association for Clinical Oncology, follows:

“ASCO appreciates the Senate prioritizing funding for cancer research. The funding included in this bill represents a bipartisan commitment to ensure continued innovation and advancement in cancer research. It is our responsibility as a nation to provide necessary resources to accelerate progress to ensure more lives are saved from this disease.

“There are a record 17 million cancer survivors in the United States today due, in large part, to federal investment in cancer research. Our past investments have yielded remarkable results and we urge Congress to continue its strong support of scientific advancement through investments in NIH, NCI, and ARPA-H.

“We look forward to working with lawmakers as they move ahead with a final appropriations bill that reflects their dedication to cancer prevention, early detection, treatment, and survivorship.” 

Bookmark ASCO in Action for updates, as well as news, advocacy, and analysis on cancer policy.